Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06199466 · ClinicalTrials.gov registry record · Phase 1
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT06199466: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT06199466 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06199466, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG YL-13027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2025-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06199466
The ClinicalTrials.gov registry entry for NCT06199466 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT06199466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06199466 about?
NCT06199466 is a clinical study titled "A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer". To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
What is the current status of trial NCT06199466?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2024-01-22. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT06199466?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), YL-13027 (DRUG).
Who is sponsoring clinical trial NCT06199466?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.